Expression of DLL3 and SEZ6 in the Spectrum of Neuroendocrine Neoplasia

Endocrine Pathology · Published 2025-07-23 · DOI 10.1007/s12022-025-09873-0

Free full text

Authors being retrieved — see the publisher record. https://doi.org/10.1007/s12022-025-09873-0

Abstract

PubPorta does not have an abstract for this article yet.

Read the article at the publisher →

Publication details

Year

2025

Related articles

• DLL3-Targeted Strategies in Advanced Prostate Cancer: Current Evidence and Future Perspectives · Drugs · 2026 · Cites or is cited by this article
• Advancing antibody drug conjugates in gastrointestinal cancers · British Journal of Cancer · 2026 · Cites or is cited by this article
• An Integrative RNA Spliceosomic Landscape of Pancreatic Neuroendocrine Tumors Identifies Clinically Relevant Molecular Subgroups · Endocrine Pathology · 2026 · Same journal
• Expansion of Germline Variants in Primary Hyperparathyroidism: Fumarate Hydratase Deficiency as a Cause of Parathyroid Adenomas · Endocrine Pathology · 2026 · Same journal
• A Cauda Equina Neuroendocrine Tumor with Tyrosine Hydroxylase Expression · Endocrine Pathology · 2026 · Same journal
• Histopathological and Molecular Characteristics of Pediatric Adrenocortical Tumors: where Do we Stand? · Endocrine Pathology · 2026 · Same journal
• Prognostic Features in Surgically Resected Well-Differentiated Pancreatic Neuroendocrine Tumors: an Analysis of 904 Patients with 7882 Person-Years of Follow-Up · Endocrine Pathology · 2025 · Same journal
• Phenotypic Landscape of Pulmonary Neuroendocrine Tumors: Subtyped by OTP/ASCL1 Expression Correlated with Histology, Hormones and Outcome · Endocrine Pathology · 2025 · Same journal
• Recipient of the 2025 Endocrine Pathology Society Lifetime Achievement Award: Dr. Arthur S. Tischler, M.D. · Endocrine Pathology · 2025 · Same journal
• Multi-center Assessment of DLL3 Expression by Immunohistochemistry in Medullary Thyroid Carcinoma · Endocrine Pathology · 2025 · Same journal